Source comparison
BPC-157 Rheumatoid Arthritis Mechanism: Comparison
BPC-157 NF-κB downregulation in synovial tissue Reduces TNF-α and IL-1β production locally Promotes Type II collagen synthesis and angiogenesis No—acts locally without systemic immune modulation Promising preclinical data; no human RCTs as of 2026; theoretical
This comparison does not assign a generated winner or score.
- BPC-157
- NF-κB downregulation in synovial tissue
- Reduces TNF-α and IL-1β production locally
- Promotes Type II collagen synthesis and angiogenesis
- No—acts locally without systemic immune modulation
- Promising preclinical data; no human RCTs as of 2026; theoretically addresses both inflammation and repair
- Methotrexate
- Inhibits dihydrofolate reductase (blocks DNA synthesis in rapidly dividing cells)
- Indirect reduction via reduced immune cell proliferation
- None—purely anti-inflammatory
- Yes—broad immunosuppression; increased infection risk
- Gold standard DMARD; effective for symptom control but does not restore cartilage
- Anti-TNF Biologics (Adalimumab, Etanercept)
- Binds circulating TNF-α; prevents receptor activation
- Blocks TNF-α signaling systemically
- None—prevents further damage but does not repair existing erosion
- Yes—blocks TNF-α across all tissues; increases infection and malignancy risk
- Highly effective for halting progression; expensive; requires ongoing administration
- NSAIDs (Ibuprofen, Naproxen)
- COX enzyme inhibition (blocks prostaglandin synthesis)
- No direct cytokine effect—symptomatic relief only
- None—no effect on cartilage metabolism
- No
- First-line for pain management; does not modify disease progression; GI and cardiovascular risks with chronic use